For: | Zhang CY, Liu S, Yang M. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy. World J Gastroenterol 2022; 28(27): 3346-3358 [PMID: 36158267 DOI: 10.3748/wjg.v28.i27.3346] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v28/i27/3346.htm |
Number | Citing Articles |
1 |
Zachary J. Brown, Samantha M. Ruff, Timothy M. Pawlik. The effect of liver disease on hepatic microenvironment and implications for immune therapy. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1225821
|
2 |
Chunye Zhang, Yuxiang Sui, Shuai Liu, Ming Yang. In vitro and in vivo experimental models for cancer immunotherapy study. Current Research in Biotechnology 2024; 7: 100210 doi: 10.1016/j.crbiot.2024.100210
|
3 |
Pietro Guerra, Andrea Martini, Patrizia Pontisso, Paolo Angeli. Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma. Cancers 2023; 15(14): 3629 doi: 10.3390/cancers15143629
|
4 |
Kah Ming Wong, Yong Hui Wong, Sau Har Lee. In Silico Discovery of LL13, a Shortened Pardaxin 6 Peptide Derivative with Anti-proliferative Activity. International Journal of Peptide Research and Therapeutics 2024; 30(4) doi: 10.1007/s10989-024-10615-9
|
5 |
Lien-Hung Huang, Cheng-Shyuan Rau, Yueh-Wei Liu, Chia-Jung Wu, Peng-Chen Chien, Hui-Ping Lin, Yi-Chan Wu, Chun-Ying Huang, Ting-Min Hsieh, Ching-Hua Hsieh. Exploring the Regulatory Role of XIST-microRNAs/mRNA Network in Circulating CD4+ T Cells of Hepatocellular Carcinoma Patients. Biomedicines 2023; 11(7): 1848 doi: 10.3390/biomedicines11071848
|
6 |
Alexsis Garcia, Stephen O. Mathew. Racial/Ethnic Disparities and Immunotherapeutic Advances in the Treatment of Hepatocellular Carcinoma. Cancers 2024; 16(13): 2446 doi: 10.3390/cancers16132446
|
7 |
Chunye Zhang, Yuxiang Sui, Shuai Liu, Ming Yang. Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Exploration of Digestive Diseases 2023; : 246 doi: 10.37349/edd.2023.00029
|
8 |
Atieh Pourbagheri‐Sigaroodi, Majid Momeny, Nima Rezaei, Fatemeh Fallah, Davood Bashash. Immune landscape of hepatocellular carcinoma: From dysregulation of the immune responses to the potential immunotherapies. Cell Biochemistry and Function 2024; 42(5) doi: 10.1002/cbf.4098
|
9 |
Safia Obaidur Rab, R. Roopashree, Farag M. A. Altalbawy, M. Ravi Kumar, Mamata Chahar, Manmeet Singh, Aziz Kubaev, Hassan Thoulfikar A. Alamir, Faraj Mohammed, Abed J. Kadhim, Merwa Alhadrawi. Phytochemicals and Their Nanoformulations for Targeting Hepatocellular Carcinoma: Exploring Potential and Targeting Strategies. Cell Biochemistry and Function 2024; 42(8) doi: 10.1002/cbf.70013
|
10 |
Gaocheng Wang, Jingjing Wang, Shuilin Dong, Zhanguo Zhang, Wanguang Zhang, Jianping Zhao. Immune checkpoint inhibitor‑associated diabetes mellitus in patients with HCC: Report of three cases and literature review. Experimental and Therapeutic Medicine 2024; 27(5) doi: 10.3892/etm.2024.12486
|
11 |
Ming Yang, Ethan Vanderwert, Eric T. Kimchi, Kevin F. Staveley-O’Carroll, Guangfu Li. The Important Roles of Natural Killer Cells in Liver Fibrosis. Biomedicines 2023; 11(5): 1391 doi: 10.3390/biomedicines11051391
|
12 |
Xize Wu, Changbin Yuan, Jiaxiang Pan, Yi Zhou, Xue Pan, Jian Kang, Lihong Ren, Lihong Gong, Yue Li. CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-66287-4
|
13 |
Zhanao He, Jie Zhang, Wukui Huang. Diagnostic role and immune correlates of programmed cell death-related genes in hepatocellular carcinoma. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-47560-4
|
14 |
Chun-Ye Zhang, Shuai Liu, Ming Yang. Treatment of liver fibrosis: Past, current, and future. World Journal of Hepatology 2023; 15(6): 755-774 doi: 10.4254/wjh.v15.i6.755
Abstract(722) |
Core Tip(663) |
Full Article(HTML)(4936)
|
Full Article with Cover (PDF)-4268K(107)
|
Full Article (Word)-1195K(35)
|
Audio-303K(5)
|
Peer-Review Report-179K(61)
|
Answering Reviewers-123K(48)
|
Full Article (PDF)-1940K(421)
|
Full Article (XML)-339K(58)
|
Times Cited (27)
|
Total Visits (8981)
|
Open
|
15 |
Xinyan Wu, Zhigang Zhou, Qiang Cao, Yuquan Chen, Junling Gong, Qi Zhang, Yi Qiang, Yanfeng Lu, Guangzhu Cao. Reprogramming of Treg cells in the inflammatory microenvironment during immunotherapy: a literature review. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1268188
|
16 |
Yusra Zarlashat, Shakil Abbas, Abdul Ghaffar. Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy. Cancers 2024; 16(11): 2034 doi: 10.3390/cancers16112034
|
17 |
Lingzhen Hu, Zongren Wang, Yang Liao, Xiaomeng Jiang, Huojun Lian, Zhuoying Lin. Tumor-infiltrating T-Lymphocyte immunity-related immune tolerance and anti–programmed cell death protein 1/ligand of programmed cell death protein 1 therapy for advanced hepatocellular carcinoma. Oncology and Translational Medicine 2024; 10(4): 162 doi: 10.1097/ot9.0000000000000041
|
18 |
Mona Abd El-Rahman Abu El-Makarem, Douaa Mohammed Sayed, Ragaa Abdelshaheed Matta, Mahmoud Ragab Mohamed, Manal Ameer Abd El-Malak, Nehal Ibrahim Abbas. Interaction of peripheral CD4+CD25+CD127− Tregs with prolactin in HCV hepatocellular carcinoma: oncogenic or immunogenic mechanisms. Egyptian Liver Journal 2023; 13(1) doi: 10.1186/s43066-023-00250-2
|
19 |
Chunye Zhang, Yuxiang Sui, Shuai Liu, Ming Yang. The Roles of Myeloid-Derived Suppressor Cells in Liver Disease. Biomedicines 2024; 12(2): 299 doi: 10.3390/biomedicines12020299
|